Substituted piperazines as CB

1. A compound of Formula (I):

or a pharmaceutically acceptable salt or ester thereof, wherein:

Ar 1 and Ar 2 are each phenyl substituted with one or more groups Y 1 that are independently selected from the group consisting of (C 2 -C 6 )alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, halo, haloalkyl, benzyl, aryl, heteroaryl, —O-aryl, —S-aryl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —(O) 2 -aryl, -alkylene-CN, —CN, —C(O)-alkyl, —C(O)-aryl, —C(O)-haloalkyl, —C(O)O-alkyl, —N(R 2 )C(O)-alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O-alkyl, —O-haloalkyl, —O-alkylene-C(O)OH, —S-alkyl, —S-haloalkyl, -alkylene-OH, -alkylene-C(O)—O-alkyl, —O-alkylene-aryl, and —N(R 5 ) 2 wherein said aryl, heteroaryl, the aryl portion of said —O-aryl, the aryl portion of said —S-aryl, the aryl portion of said —S(O) 2 -aryl, the aryl portion of said benzyl, the aryl portion of said —C(O)-aryl, and the aryl portion of said —O-alkylene-aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group;

n and m are independently 0 or 1;

A is selected from the group consisting of —C(O)—, —S(O) 2 —, —C(═N—OR 2 )—, and —(C(R 2 ) 2 ) q — wherein q is 1, 2, or 3;

B is selected from the group consisting of —N(R 2 )—, —C(O)—, and —(C(R 3 ) 2 ) r — wherein r is 1 or 2,

with the proviso that when B is —C(O)—, then A is —C(O)— or —(C(R 2 ) 2 ) q —;

X is selected from the group consisting of H, alkyl, —S-alkyl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, —S(O) 2 -heteroaryl, cycloalkyl, benzo-fused cycloalkyl, benzo-fused heterocycloalkyl, benzo-fused heterocycloalkenyl, heterocycloalkyl, —C(R 2 )═C(R 2 )-aryl, —C(R 2 )═C(R 2 )-heteroaryl, —OR 2 , —O-alkylene-O-alkyl, —S-aryl, —N(R 4 ) 2 , —(C(R 2 ) 2 )—S-heteroaryl, —C(O)—O-alkyl, —C(O)-aryl, —C(O)-heteroaryl, —N═O, —C(S-alkyl)=N—S(O) 2 -aryl, —C(N(R 2 ) 2 )═N—S(O) 2 -aryl, and —(C(R 2 ) 2 ) s -aryl wherein s is 0, 1, or 2,

wherein the heteroaryl portion of said —(C(R 2 ) 2 ) s -heteroaryl, the aryl portion of said —C(R 2 )═C(R 2 )-aryl, the heteroaryl portion of said —C(R 2 )═C(R 2 )-heteroaryl, the aryl portion of said —S-aryl, the aryl portion of said —S(O) 2 -aryl, the heteroaryl portion of said —S(O) 2 -heteroaryl, the aryl portion of said —C(O)-aryl, the heteroaryl portion of said —C(O)-heteroaryl, the aryl portion of said —(C(R 2 ) 2 ) s -aryl, the aryl portion of said —C(S-alkyl)=N—S(O) 2 -aryl, the aryl portion of said —C(N(R 2 ) 2 )═N—S(O) 2 -aryl, the benzo portion of said benzo-fused cycloalkyl, the benzo portion of said benzo-fused heterocycloalkyl, and the benzo portion of said benzo-fused heterocycloalkenyl of X are unsubstituted or substituted with one or more groups Y 1 that are independently selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, halo, haloalkyl, benzyl, aryl, heteroaryl, —O-aryl, —S-aryl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, -alkylene-CN, —C(O)-alkyl, —C(O)-aryl, —C(O)-haloalkyl, —C(O)O-alkyl, —N(R 2 )C(O)-alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , R 2 —OH —O-alkyl, —O-haloalkyl, —O-alkylene-C(O)(OH), S-alkyl, —S-haloalkyl, -alkylene-OH, -alkylene-C(O)—O-alkyl, —O-alkylene-aryl, and —N(R 5 ) wherein said aryl, heteroaryl, the aryl portion of said —O-aryl, the aryl portion of said —S-aryl, the aryl portion of said —S(O) 2 aryl, the aryl portion of said benzyl, the aryl portion of said —C(O)-aryl, and the aryl portion of said —O-alkylene-aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH z —O— group; and

said cycloalkyl, the cycloalkyl portion of said —S(O) 2 -cycloalkyl, said heterocycloalkyl, the cycloalkyl portion of said benzo-fused cycloalkyl, the heterocycloalkyl portion of said benzo-fused heterocycloalkyl, and the heterocycloalkenyl portion of said benzo-fused heterocycloalkenyl of X are unsubstituted or substituted with one or more groups Y 2 ;

with the proviso that the group X—(B) n -(A) m -, taken as a group, is not selected from the group consisting of —C(R 2 )═C(R 2 )-aryl and —(C(R 2 ) 2 ) s -aryl wherein s is 0, 1, or 2,

wherein the aryl portion of said —C(R 2 )═C(R 2 )-aryl and the aryl portion of said —(C(R 2 ) 2 ) s -aryl of X are unsubstituted or substituted with one or more groups Y 1 independently selected from the group consisting of alkyl, cycloalkyl, halo, haloalkyl, benzyl, aryl, —O-aryl, —S-aryl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, -alkylene-CN, —CN, —C(O)-alkyl, —C(O)-aryl, —C(O)-haloalkyl, —C(O)O-alkyl, —N(R 2 )C(O)-alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O-alkyl, —O-haloalkyl, —O-alkylene-C(O)OH, —S-alkyl, —S-haloalkyl, -alkylene-OH, -alkylene-C(O)—O-alkyl, —O-alkylene-aryl, and —N(R 5 ) 2 ,

wherein said aryl and the aryl portion of said —O-aryl, —S-aryl, —S(O) 2 -aryl, benzyl, —C(O)-aryl, and —O-alkylene-aryl of Y 1 are unsubstituted or substituted with one or more groups Z;

each R 1 is independently selected from the group consisting of alkyl, haloalkyl, -alkylene-N(R 5 ) 2 , -alkylene-OR 2 , alkylene-N 3 , -alkylene-CN, and alkylene-O—S(O) 2 -alkyl; or

two R 1 groups attached to the same ring carbon atom form a carbonyl group;

p is 0, 1, 2, 3, or 4;

each R 2 is independently H, alkyl, or aryl,

wherein said aryl of R 2 is unsubstituted or substituted with one or more groups Y 1 that are independently selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, halo, haloalkyl, benzyl, a heteroaryl, —O-aryl, —S-aryl, —(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, -alkylene-CN, —CN, —C(O)-alkyl, —C(O)-aryl, —C(O)-haloalkyl, —C(O)O-alkyl, —N(R 2 )C(O)-alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O-alkyl, —O-haloalkyl, —O-alkylene-C(O)OH, —S-alkyl, —S-haloalkyl, -alkylene-OH, -alkylene-C(O)—O-alkyl, —O-alkylene-aryl, and —N(R 5 ) wherein said aryl, heteroaryl, the aryl portion of said —O-aryl, the aryl portion of said —S-aryl the aryl portion of said —S(O)-aryl the aryl portion of said benzyl, the aryl portion of said —C(O)-aryl, and the aryl portion of said —O-alkylene-aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group;

each R 3 is independently selected from the group consisting of H, alkyl, unsubstituted aryl, —OR 2 , -alkylene-O-alkyl, -alkylene-OH and aryl substituted with one or more Y 1 groups that are independently selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, halo, haloalkyl, benzyl, aryl, heteroaryl, —O-aryl, —S-aryl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, -alkylene-CN, —CN, —C(O)-alkyl, —C(O)-aryl, —C(O)-haloalkyl, —C(O)O-alkyl, —N(R 2 )C(O)-alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O-alkyl, —O-haloalkyl, —O-alkylene-C(O)OH, —S-alkyl, —S-haloalkyl, -alkylene-OH, -alkylene-C(O)—O-alkyl, —O-alkylene-aryl, and —N(R 5 ) 2 wherein said aryl, heteroaryl, the aryl portion of said —O-aryl, the aryl portion of said —S-aryl, the aryl portion of said —S(O) 2 -aryl, the aryl portion of said benzyl, the aryl portion of said —C(O)-aryl, and the aryl portion of said —O-alkylene-aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH z —O— group;

each R 4 is independently selected from the group consisting of H, alkyl, aryl, —C(O)—O-alkyl, —C(O)-alkyl, —C(O)-aryl, and —S(O) 2 aryl,

wherein said aryl, the aryl portion of said —C(O)-aryl, and the aryl portion of said —S(O) 2 aryl of R 4 are unsubstituted or substituted with one or more Y 1 groups that are independently selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, heterocycloalkenyl, halo, haloalkyl, benzyl, aryl, heteroaryl, —O-aryl, —S-aryl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, -alkylene-CN, —CN, —C(O)-alkyl, —C(O)-aryl, —C(O)-haloalkyl, —C(O)O-alkyl, —N(R 2 )C(O)-alkyl, —N(R 2 )C(O)—N(R 2 )—OH, —O-alkyl, —O-haloalkyl, —O-alkylene-C(O)OH, —S-alkyl, —S-haloalkyl, -alkylene-OH, -alkylene-C(O)—O-alkyl, —O-alkylene-aryl, and —N(R 5 ) 2 wherein said aryl, heteroaryl, the aryl portion of said —O-aryl, the aryl portion of said —S-aryl, the aryl portion of said —S(O) 2 -aryl, the aryl portion of said benzyl, the aryl portion of said —C(O)-aryl, and the aryl portion of said —O-alkylene-aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 — group;

each R 5 is independently selected from the group consisting of H, alkyl, aryl, —S(O) 2 -alkyl, —S(O) 2 -cycloalkyl, —S(O) 2 -aryl, —C(O)—N(R 2 ) 2 , —C(O)-alkyl, and -alkylene-OH,

wherein said aryl and the aryl portion of said —S(O) 2 -aryl of R 5 are unsubstituted or substituted with one or more Z groups;

each Y 2 is independently selected from the group consisting of alkyl, haloalkyl, aryl, -alkylene-aryl, —CN, —C(O)-alkyl, —S(O) 2 -cycloalkyl, -alkylene-N(R 4 ) 2 , —C(O)-alkylene-N(R 4 ) 2 , —C(O)—O-alkyl, —C(O)-aryl, and —C(O)-haloalkyl,

wherein said aryl and the aryl portion of said —C(O)-aryl of Y 2 are unsubstituted or substituted with one or more groups Z; or

two groups Y 2 form a —O—CH 2 CH 2 —O— group; or

two of said Y 2 substituents attached to the same ring carbon atom of a cycloalkyl, benzo-fused cycloalkyl, benzo-fused heterocycloalkyl, benzo-fused heterocycloalkenyl, or heterocycloalkyl ring, together with the ring carbon atom to which they are both attached, form a carbonyl group; and

each Z is independently selected from the group consisting of alkyl, halo, haloalkyl, —OH, —O-alkyl, and —CN.

2. The compound of claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

Ar 1 and Ar 2 are each phenyl substituted with one or more groups Y 1 that are independently selected from the group consisting of (C 2 -C 6 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 10 )heterocycloalkyl, (C 2 -C 10 )heterocycloalkenyl, halo, (C 1 -C 6 )haloalkyl, benzyl, (C 6 -C 10 )aryl, (C 2 -C 10 )heteroaryl, —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-CN, —CN, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, —C(O)—(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkylene-C(O)OH, —S—(C 1 -C 6 )alkyl, —S—(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-OH, —(C 1 -C 6 )alkylene-C(O)—O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, and —N(R 5 ) 2 , wherein said (C 6 -C 10 )aryl, said (C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —O—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl said benzyl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, and the (C 6 -C 10 )aryl portion of said —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group;

X is selected from the group consisting of H, (C 1 -C 6 )alkyl, —S—(C 1 -C 6 )alkyl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —S(O) 2 —(C 2 -C 10 )heteroaryl, (C 3 -C 10 )cycloalkyl, benzo-fused (C 3 -C 10 )cycloalkyl, benzo-fused (C 2 -C 10 )heterocycloalkyl, benzo-fused (C 2 -C 10 )heterocycloalkenyl, (C 2 -C 10 )heterocycloalkyl, —C(R 2 )═C(R 2 )—(C 6 -C 10 )aryl, —C(R 2 )═C(R 2 )—(C 2 -C 10 )heteroaryl, —OR 2 , —O—(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —S—(C 6 -C 10 )aryl, —N(R 4 ) 2 , —(C(R 2 ) 2 ) s —(C 2 -C 10 )heteroaryl, —C(O)—O—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, —C(O)—(C 2 -C 10 )heteroaryl, —N═O, —C(S—(C 1 -C 6 )alkyl)=N—S(O) 2 —(C 6 -C 10 )aryl, —C(N(R 2 ) 2 )═N—S(O) 2 —(C 6 -C 10 )aryl, and —(C(R 2 ) 2 ) s —(C 6 -C 10 )aryl wherein s is 0, 1, or 2,

wherein the (C 2 -C 10 )heteroaryl portion of said —(C(R 2 ) 2 ) s —(C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —C(R 2 )═C(R 2 )—(C 6 -C 10 )aryl, the (C 2 -C 10 )heteroaryl portion of said —C(R 2 )═C(R 2 )—(C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —S—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl, the (C 2 -C 10 )heteroaryl portion of said —S(O) 2 —(C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, the (C 2 -C 10 )heteroaryl portion of said —C(O)—(C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —(C(R 3 ) 2 ) s —(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —C(S—(C 1 -C 6 )alkyl)=N—S(O) 2 —(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —C(N(R 2 ) 2 )═N—S(O) 2 —(C 6 -C 10 )aryl, the benzo portion of said benzo-fused (C 3 -C 10 )cycloalkyl, the benzo portion of said benzo-fused (C 2 -C 10 )heterocycloalkyl, and the benzo portion of said benzo-fused (C 2 -C 10 )heterocycloalkenyl of X are unsubstituted or substituted with one or more groups Y 1 that are independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 10 )heterocycloalkyl, (C 2 -C 10 )heterocycloalkenyl, halo, (C 1 -C 6 )haloalkyl, benzyl, (C 6 -C 10 )aryl, (C 2 -C 10 )heteroaryl), —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-CN, —CN, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, —C(O)—C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkylene-C(O)OH, —S—(C 1 -C 6 )alkyl, —S—(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-OH, —(C 1 -C 6 )alkylene-C(O)—O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, and —N(R 5 ) 2 , wherein said (C 6 -C 10 )aryl, said (C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —(O)—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl, said benzyl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, and the (C 6 -C 10 )aryl portion of —(O)—(C 1 -C 10 )aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group; and

said (C 3 -C 10 )cycloalkyl, the (C 3 -C 10 )cycloalkyl portion of said —S(O) 2 —(C 3 -C 10 )cycloalkyl, said (C 2 -C 10 )heterocycloalkyl, the (C 3 -C 10 )cycloalkyl portion of said benzo-fused (C 3 -C 10 )cycloalkyl, the (C 2 -C 10 )heterocycloalkyl portion of said benzo-fused (C 2 -C 10 )heterocycloalkyl, and the (C 2 -C 10 )heterocycloalkenyl portion of said benzo-fused (C 2 -C 10 )heterocycloalkenyl of X are unsubstituted or substituted with one or more groups Y 2 ;

with the proviso that the group X—(B) n -(A) m - is not alkyl nor is it selected from the group consisting of —C(R 2 )═C(R 2 )—(C 6 -C 10 )aryl and —(C(R 2 ) 2 ) s —(C 6 -C 10 )aryl wherein s is 0, 1, or 2, wherein the (C 6 -C 10 )aryl portion of said —C(R 2 )═C(R 2 )—(C 6 -C 10 )aryl and the (C 6 -C 10 )aryl portion of said —(C(R 3 ) 2 ) s —(C 6 -C 10 )aryl of X are unsubstituted or substituted with one or more groups Y 1 independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 10 )cycloalkyl, halo, (C 1 -C 6 )haloalkyl, benzyl, (C 6 -C 10 )aryl, (C 2 -C 10 )heteroaryl, —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-CN, —CN, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, —C(O)—(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkylene-C(O)OH, —S—(C 1 -C 6 )alkyl, —S—(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-OH, —(C 1 -C 6 )alkylene-C(O)—O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, and —N(R 5 ) 2 , wherein said (C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 6 -C 10 )aryl, benzyl, —C(O)—(C 6 -C 10 )aryl, and the —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl of Y 1 are unsubstituted or substituted with one or more groups Z;

each R 1 is independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-N(R 5 ) 2 , —(C 1 -C 6 )alkylene-OR 2 , —(C 1 -C 6 )alkylene-N 3 , —(C 1 -C 6 )alkylene-CN, and (C 1 -C 6 )alkylene-O—S(O) 2 —(C 1 -C 6 )alkyl, or

two R 1 groups attached to the same ring carbon atom form a carbonyl group;

p is 0, 1, 2, 3, or 4;

each R 2 is independently H, (C 1 -C 6 )alkyl, or (C 6 -C 10 )aryl,

wherein said (C 6 -C 10 )aryl of R 2 is unsubstituted or substituted with one or more groups Y 1 that are independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 10 )heterocycloalkyl, (C 2 -C 10 )heterocycloalkenyl, halo, (C 1 -C 6 )haloalkyl, benzyl, (C 6 -C 10 )aryl, (C 2 -C 10 )heteroaryl, —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-CN, —CN, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, —C(O)—(C 1 -C 6 haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkylene-C(O)OH, —S—(C 1 -C 6 )alkyl, —S—(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-OH, —(C 1 -C 6 )alkylene-C(O)—O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, and —N(R 5 ) wherein said (C 6 -C 10 )aryl, said (C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —O—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl, said benzyl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, and the (C 6 -C 10 )aryl portion of said —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group;

each R 3 is independently selected from the group consisting of H, (C 1 -C 6 )alkyl, unsubstituted (C 6 -C 10 )aryl, —OR 2 , —(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylene-OH and (C 6 -C 10 )aryl substituted with one or more Y 1 groups that are independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 10 )heterocycloalkyl, (C 2 -C 10 )heterocycloalkenyl, halo, (C 1 -C 6 )haloalkyl, benzyl, (C 6 -C 10 )aryl, (C 2 -C 10 )heteroaryl, —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-CN, —CN, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 1 -C 10 )aryl, —C(O)—(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkylene-C(O)OH, —S—(C 1 -C 6 )alkyl, —S—(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-OH, —(C 1 -C 6 )alkylene-C(O)—O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, and —N(R 5 ) 2 , wherein (C 1 -C 10 )aryl, said (C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —O—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl, said benzyl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, and the (C 6 -C 10 )aryl portion of said —O—(C 1 -C 6 )aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group;

each R 4 is independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, —C(O)—O—(C 1 -C 6 )alkyl, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, and —S(O) 2 —(C 6 -C 10 )aryl,

wherein said (C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, and the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl of R 4 are unsubstituted or substituted with one or more Y 1 groups that are independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 10 )heterocycloalkyl, (C 2 -C 10 )heterocycloalkenyl, halo, C 1 -C 6 haloalkyl, benzyl, (C 6 -C 10 )aryl, (C 2 -C 10 )heteroaryl, —O—(C 6 -C 10 )aryl, —S—(C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 —(C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-CN, —CN, —C(O)—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, —C(O)—(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—(C 1 -C 6 )alkyl, —N(R 2 )C(O)—N(R 2 ) 2 , —OH, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkylene-C(O)OH, —S—(C 1 -C 6 )alkyl, —S—(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkylene-OH, —(C 1 -C 6 )alkylene-C(O)—O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, and —N(R 5 ) 2 , wherein said (C 6 -C 10 )aryl, said (C 2 -C 10 )heteroaryl, the (C 6 -C 10 )aryl portion of said —O—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S—(C 6 -C 10 )aryl, the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl, said benzyl, the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl, and the (C 6 -C 10 )aryl portion of said —O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl of Y 1 are unsubstituted or substituted with one or more groups Z; or two groups Y 1 form a —O—CH 2 —O— group;

each R 5 is independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, —S(O) 2 —(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —S(O) 2 -aryl, —C(O)—N(R 2 ) 2 , —C(O)—(C 1 -C 6 )alkyl, and —(C 1 -C 6 )alkylene-OH,

wherein said (C 6 -C 10 )aryl and the (C 6 -C 10 )aryl portion of said —S(O) 2 —(C 6 -C 10 )aryl of R 5 are unsubstituted or substituted with one or more Z groups;

each Y 2 is independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 6 -C 10 )aryl, —(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, —CN, —C(O)—(C 1 -C 6 )alkyl, —S(O) 2 —(C 3 -C 10 )cycloalkyl, —(C 1 -C 6 )alkylene-N(R 2 ) 2 , —C(O)—(C 1 -C 6 )alkylene-N(R 4 ) 2 , —C(O)—O—(C 1 -C 6 )alkyl, —C(O)—(C 6 -C 10 )aryl, and —C(O)—(C 1 -C 6 )haloalkyl,

wherein said (C 6 -C 10 )aryl and the (C 6 -C 10 )aryl portion of said —C(O)—(C 6 -C 10 )aryl of Y 2 are unsubstituted or substituted with one or more groups Z; or

two groups Y 2 form a —O—CH 2 CH 2 —O— group; or

two of said Y 2 substituents attached to the same ring carbon atom of a (C 3 -C 10 )cycloalkyl, benzo-fused (C 3 -C 10 )cycloalkyl, benzo-fused (C 2 -C 10 )heterocycloalkyl, benzo-fused (C 2 -C 10 ) heterocycloalkenyl, or (C 2 -C 10 )heterocycloalkyl ring, together with the ring carbon atom to which they are both attached, form a carbonyl group; and

each Z is independently selected from the group consisting of (C 1 -C 6 )alkyl, halo, (C 1 -C 6 )haloalkyl, —OH, —O—(C 1 -C 6 )alkyl, and —CN.

3. The compound of claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

Ar 2 is a phenyl independently substituted with two Y 1 groups.

4. The compound of claim 3 , or a pharmaceutically acceptable salt or ester thereof, wherein:

Ar 2 is a phenyl independently substituted with two Y 1 groups at the 2- and 4-position.

5. The compound of claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

Ar 1 is a phenyl substituted with one Y 1 group at the 4-position.

6. The compound of claim 5 , or a pharmaceutically acceptable salt or ester thereof, wherein:

Ar 2 is a phenyl independently substituted with two Y 1 groups at the 2- and 4-position.

7. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 1; and

A is —C(O)—.

8. The compound according to claim 7 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 0.

9. The compound according to claim 7 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 1; and B is —NH—.

10. The compound according to claim 7 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 1; and B is —(C(R 2 ) 2 ) r — wherein r is 1 or 2.

11. The compound according to claim 7 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 1; and B is —N(R 2 )—.

12. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 1; and A is —S(O) 2 —.

13. The compound according to claim 12 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 0.

14. The compound according to claim 12 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 1; and B is —N(R 2 )—.

15. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 1; A is —C(═N—OR 2 )—; and n is 0.

16. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 1; A is —(C(R 2 ) 2 ) q — wherein q is 1, 2, or 3; and n is 0.

17. The compound according to claim 16 , wherein X is heteroaryl, and said heteroaryl of X is unsubstituted or substituted with one or more Y 1 groups.

18. The compound according to claim 17 , wherein q is 1 or 2.

19. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 0; B is —(C(R 3 ) 2 ) r — wherein r is 1, 2, or 3.

20. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m and n are both 1; and

B is —(C(R 3 ) 2 ) r — wherein r is 1, 2, or 3.

21. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m and n are both 0.

22. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

X is —(C(R 2 ) 2 ) s -aryl wherein s is 0, 1, or 2.

23. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

X is heteroaryl.

24. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

X is cycloalkyl.

25. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

X is heterocycloalkyl.

26. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

X is alkyl.

27. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

X is —N(R 4 ) 2 .

28. The compound according to claim 20 , or a pharmaceutically acceptable salt or ester thereof, wherein:

A is —C(O)—.

29. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m and n are both 1; A is —C(O)—; and B is —NH—.

30. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, having the following Formula (IA):

31. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, having the following Formula (IA):

32. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, having the following Formula (IB):

33. The compound according to claim 32 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 1; and A is —C(O)—.

34. The compound according to claim 33 , or a pharmaceutically acceptable salt or ester thereof, wherein n is 0.

35. The compound according to claim 33 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 1; and B is —N(R 2 )—.

36. The compound according to claim 32 , or a pharmaceutically acceptable salt or ester thereof, wherein:

m is 1; A is —S(O) 2 —.

37. The compound according to claim 36 , or a pharmaceutically acceptable salt or ester thereof, wherein n is 0.

38. The compound according to claim 36 , or a pharmaceutically acceptable salt or ester thereof, wherein:

n is 1; and B is —N(R 2 )—.

39. A compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, selected from the group consisting of:

40. A compound of claim 1 selected from the group consisting of:

or a pharmaceutically acceptable salt or ester thereof.

41. A compound of the following formula:

or a pharmaceutically acceptable salt or ester thereof.

42. A compound of the following formula:

or a pharmaceutically acceptable salt or ester thereof.

43. A compound of claim 1 selected from the group consisting of:

or a pharmaceutically acceptable salt or ester thereof.

44. The compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof, in purified form.

45. A composition comprising:

at one compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof; and a pharmaceutically acceptable carrier.

46. A method of treating, reducing, or ameliorating in a patient in need thereof, comprising:

administering to said patient an effective amount of at least one compound according to claim 1 , or a pharmaceutically acceptable salt or ester thereof.

47. A method of treating, reducing, or ameliorating in a patient in need thereof, comprising:

administering to said patient an effective amount of a composition according to claim 45 .

48. A composition comprising:

at one compound of Formula (I) according to claim 1 , or a pharmaceutically acceptable salt or ester thereof; and

at least one cholesterol lowering compound.

49. The composition of claim 48 , wherein said at least one cholesterol lowering compound is at least one sterol absorption inhibitor or at least one 5α-stanol absorption inhibitor.

50. The composition of claim 48 , wherein said at least one cholesterol lowering compound is at least one substituted azetidinone compound or substituted β-lactam compound or a pharmaceutically acceptable salt or ester thereof.

51. The composition of claim 50 , wherein said at least one cholesterol lowering compound is ezetimibe.